We scan new podcasts and send you the top 5 insights daily.
In the HER2CLIMB-05 trial, 55% of patients with ER-positive tumors did not receive concurrent endocrine therapy despite study protocol allowances. Dr. Hamilton noted that those who received endocrine therapy achieved much longer progression-free survival, highlighting a crucial treatment opportunity during chemotherapy de-escalation.
Data from the PERTAIN trial's non-induction subgroup shows a significant PFS benefit (26.6 months) with dual HER2 blockade plus endocrine therapy. This supports a chemotherapy-free initial strategy for carefully selected patients with indolent, clinically stable disease.
Professor Loibl questions the necessity of aggressive ovarian suppression (GnRH analogs) for premenopausal patients with HER2+/HR+ metastatic breast cancer. Since HER2 is the dominant driver, less intensive endocrine therapy, such as tamoxifen, may be a reasonable maintenance strategy, especially when combined with a CDK4/6 inhibitor.
Despite compelling data from trials like PATINA, some patients with ER+/HER2+ breast cancer refuse maintenance endocrine therapy due to side effects. This highlights a real-world gap between clinical trial evidence and patient adherence, forcing oncologists to navigate patient preferences against optimal treatment protocols.
The dramatic results of the PATINA trial reignited conversation around the crucial role and optimal utilization of endocrine therapy in HER2-positive, ER-positive metastatic breast cancer, a topic previously overshadowed by anti-HER2 treatments.
In premenopausal patients, chemotherapy's observed benefit may be an indirect effect of inducing menopause, rather than its cell-killing properties. The ongoing OFFSET trial is testing if optimizing endocrine therapy with ovarian suppression can achieve the same risk reduction as chemotherapy, potentially avoiding chemo's side effects entirely for this group.
Even within recent major clinical trials like HER2CLIMB-05, less than half of eligible hormone receptor-positive patients received endocrine therapy. This highlights a critical and widespread gap in clinical practice, as this treatment adds significant benefit.
The degree of hormone receptor positivity can guide maintenance strategy. In patients with strongly ER/PR-positive tumors, an endocrine-based approach like the PATINA regimen may be favored. Conversely, in low ER/PR expressing tumors, a more HER2-focused regimen could be more effective.
While the HER2 pathway is the dominant driver for achieving an initial tumor response in HER2+/HR+ disease, targeting the ER pathway is critical for maintaining that response and achieving long-term benefit. This dual-targeting benefit becomes more apparent over extended periods, as seen in the Affinity trial.
Based on recent trial data, the optimal maintenance strategy for HER2+ metastatic breast cancer differs by subtype. The speaker suggests palbociclib for hormone receptor-positive patients and tucatinib for hormone receptor-negative patients, reflecting a personalized, data-driven treatment approach.
While oncologists often continued therapy post-induction, recent trials like PATINA and HER2CLIM-05 have formally defined and validated the "maintenance treatment" concept. This provides a new, evidence-backed framework for prolonging response after initial chemotherapy cycles are complete.